Study: Marijuana May Have Therapeutic Applications in the Neuropsychopharmacology Field
Marijuana may have possible therapeutic applications in the neuropsychopharmacology field, according to a new study published in the journal European Neuropsychopharmacology, and titled Possible therapeutic applications of cannabis in the neuropsychopharmacology field.
“Cannabis use induces a plethora of actions on the CNS via its active chemical ingredients, the so-called phytocannabinoids”, states researchers. “These compounds have been frequently associated with the intoxicating properties of cannabis preparations. However, not all phytocannabinoids are psychotropic, and, irrespective of whether they are psychotropic or not, they have also shown numerous therapeutic properties.”
These properties are mostly associated with their ability to modulate the activity of an intercellular communication system, the so-called endocannabinoid system, “which is highly active in the CNS and has been found altered in many neurological disorders.”
“Specifically, this includes the neuropsychopharmacology field, with diseases such as schizophrenia and related psychoses, anxiety-related disorders, mood disorders, addiction, sleep disorders, post-traumatic stress disorder, anorexia nervosa and other feeding-related disorders, dementia, epileptic syndromes, as well as autism, fragile X syndrome and other neurodevelopment-related disorders”, states the study. “Here, we gather, from a pharmacological and biochemical standpoint, the recent advances in the study of the therapeutic relevance of the endocannabinoid system in the CNS, with especial emphasis on the neuropsychopharmacology field.”
They also “illustrate the efforts that are currently being made to investigate at the clinical level the potential therapeutic benefits derived from elevating or inhibiting endocannabinoid signaling in animal models of neuropsychiatric disorders.”
The study’s abstract:
Cannabis use induces a plethora of actions on the CNS via its active chemical ingredients, the so-called phytocannabinoids. These compounds have been frequently associated with the intoxicating properties of cannabis preparations. However, not all phytocannabinoids are psychotropic, and, irrespective of whether they are psychotropic or not, they have also shown numerous therapeutic properties. These properties are mostly associated with their ability to modulate the activity of an intercellular communication system, the so-called endocannabinoid system, which is highly active in the CNS and has been found altered in many neurological disorders. Specifically, this includes the neuropsychopharmacology field, with diseases such as schizophrenia and related psychoses, anxiety-related disorders, mood disorders, addiction, sleep disorders, post-traumatic stress disorder, anorexia nervosa and other feeding-related disorders, dementia, epileptic syndromes, as well as autism, fragile X syndrome and other neurodevelopment-related disorders. Here, we gather, from a pharmacological and biochemical standpoint, the recent advances in the study of the therapeutic relevance of the endocannabinoid system in the CNS, with especial emphasis on the neuropsychopharmacology field. We also illustrate the efforts that are currently being made to investigate at the clinical level the potential therapeutic benefits derived from elevating or inhibiting endocannabinoid signaling in animal models of neuropsychiatric disorders.
Patricia Vaughn
I have been using CBD & THC for Mild Cognitive Impairment for a number of years. Both my Mother & her Mother died with Alzheimer’s. I am also pretty sure my Great Grandmother also died with it, because My Grandmother always said she “went insane”. I had started doing a lot of research before symptoms started. To “appease” my Neurologist, I tried “their” medication for a while and it did nothing for me. My Neurologist admited that they needed to keep looking. So far a CBD capsule at 11AM & 5PM and a THC capsule at bedtime has worked VERY well for me. I will add extra or a higher dosage as needed.